SCHEMBL4164968

SCHEMBL4164968

C[C@H](N[C@H]1CCN(C(=O)OC(C)(C)C)CC1(C)C)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
GPR119 Q8TDV5 5/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.44
STS P08842 1/20 0.43
RORC P51449 2/20 0.43
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
USP30 Q70CQ3 2/20 0.41
KDM1A O60341 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28342102 1.00 KDM4E (0.48) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL15507141 1.00 KDM4E (0.48) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL4164966 1.00 KDM4E (0.48) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL16459750 1.00 KDM4E (0.48) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL25465736 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL30661567 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL19813102 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL17966350 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL17966352 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1
SCHEMBL17966353 0.88 KDM4E (0.47) KDM4EPKMGPR119NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129372-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-12-16 EP disclosed
US-10414763-B2 Azaquinazoline inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C WINDTREE THERAPEUTICS, INC. 2015-10-01 US disclosed
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C WINDTREE THERAPEUTICS, INC. 2015-10-01 US disclosed
US-20090227601-A1 Bradykinin 1 Receptor Antagonists AMGEN INC. (US) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414763-B2 Azaquinazoline inhibitors of atypical protein kinase C PRKCQ, PRKCA, PRKCZ KDM4E 1233/4885PKM 1918/4885GPR119 2202/4885
US-20090227601-A1 Bradykinin 1 Receptor Antagonists BDKRB1, BDKRB2, VIPR1 KDM4E 3759/4885PKM 1724/4885GPR119 178/4885
US-20150274720-A1 Azaquinazoline Inhibitors Of Atypical Protein Kinase C PRKCQ, PRKCA, PRKCZ KDM4E 1233/4885PKM 1918/4885GPR119 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.